March 2021; 8 (2) ArticleOpen Access
Biological Significance of Anti–SARS-CoV-2 Antibodies
Lessons Learned From Progressive Multifocal Leukoencephalopathy
Navid Manouchehri, Lawrence Steinman, Olaf Stuve
First published December 24, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000935
Navid Manouchehri
From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center.
Lawrence Steinman
From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center.
Olaf Stuve
From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center.
Biological Significance of Anti–SARS-CoV-2 Antibodies
Lessons Learned From Progressive Multifocal Leukoencephalopathy
Navid Manouchehri, Lawrence Steinman, Olaf Stuve
Neurol Neuroimmunol Neuroinflamm Mar 2021, 8 (2) e935; DOI: 10.1212/NXI.0000000000000935
Citation Manager Formats
Make Comment
See Comments

Article Figures & Data
Tables
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
COVID-19 and MS disease-modifying therapiesJoseph R. Berger, Rachel Brandstadter, Amit Bar-Or et al.Neurology: Neuroimmunology & Neuroinflammation, May 15, 2020 -
Article
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid geneShruti P. Agnihotri, Xin Dang, Jonathan L. Carter et al.Neurology, July 18, 2014 -
Views & Reviews
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 PandemicMartin S. Weber, Jacqueline A. Nicholas, Michael R. Yeaman et al.Neurology: Neuroimmunology & Neuroinflammation, September 08, 2021 -
Articles
Determinants of survival in progressive multifocal leukoencephalopathyA. Marzocchetti, T. Tompkins, D. B. Clifford et al.Neurology, November 09, 2009